A5087476818- Cancer Immunotherapy and Biomarkers
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Bladder and Urothelial Cancer Treatments
- Virus-based gene therapy research
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
- Cancer Cells and Metastasis
- Nonmelanoma Skin Cancer Studies
- Viral Infectious Diseases and Gene Expression in Insects
- Urinary and Genital Oncology Studies
- Cancer-related molecular mechanisms research
- Renal and related cancers
- Brain Metastases and Treatment
- Cancer Research and Treatments
- HER2/EGFR in Cancer Research
- Infectious Diseases and Mycology
- Cancer Mechanisms and Therapy
- Peptidase Inhibition and Analysis
- Advanced Breast Cancer Therapies
- Pancreatic and Hepatic Oncology Research
- Ferroptosis and cancer prognosis
Peking University Cancer Hospital
2016-2025
Peking University
2016-2025
Tianjin Medical University Cancer Institute and Hospital
2022-2025
Melanoma Institute Australia
2024-2025
The University of Sydney
2025
Nanjing Maternity and Child Health Care Hospital
2024
Bioscience (China)
2023-2024
Henry Ford Health System
2023-2024
Nanjing Medical University
2024
Tsinghua University
2023
Metastatic mucosal melanoma responds poorly to anti-programmed cell death-1 (PD-1) monotherapy. Vascular endothelial growth factor (VEGF) has been shown play an important immunosuppressive role in the tumor microenvironment. The combination of VEGF inhibition and PD-1 blockade provides therapeutic opportunities for patients refractory either therapy alone.We conducted a single-center, phase IB trial evaluating safety preliminary efficacy toripalimab, humanized immunoglobulin G4 monoclonal...
665 Background: This single-arm phase II trial was conducted to evaluate the efficacy and safety of neoadjuvent disitamab vedotin (DV, a HER2-targetted monoclonal antibody conjugated with monomethyl auristatin E) plus perioperative toripalimab (an anti-PD-1 inhibitor) in MIBC patients (pts) HER2 expression. The preliminary results showed promising acceptable neoadjuvant treatment DV pts HER2-expressing (Sheng, et al. ASCO Annual meeting 2024). Methods: Key eligibility criteria included...
JS001, a humanized IgG4 monoclonal antibody against the programmed death-1 (PD-1) receptor, blocks interaction of PD-1 with its ligands and promotes T cell activation in preclinical studies. This phase I study is designed to evaluate safety, tolerability, clinical activity JS001 advanced melanoma or urologic cancer patients who are refractory standard systemic therapy. In dose escalation cohorts, subjects initially received single-dose, intravenous infusion were followed for 28 days by...
PD-1 checkpoint blockade immunotherapy induces long and durable response in patients with advanced melanoma. However, only a subset of melanoma benefit from this approach. The mechanism triggering the innate resistance anti-PD-1 therapy remains unclear.Experimental Design: Whole-exome sequencing (WES) RNA (RNA-Seq) analyses were performed training cohort (n = 31) using baseline tumor biopsies treated antibody. Copy-number variations (CNVs) for genes CDK4, CCND1, CDKN2A assayed TaqMan...
Mucosal melanoma is an aggressive subtype with poor response to antiprogrammed cell death-1 (PD-1) monotherapy. Axitinib in combination toripalimab, a humanized IgG4 mAb against PD-1, showed promising rate patients metastatic mucosal (MM) phase Ib study. Here, we report the updated overall survival (OS), duration of (DoR), and biomarker analysis results.Patients advanced MM received toripalimab 1 or 3 mg/kg intravenously every 2 weeks combined axitinib 5 mg orally two times per day until...
Background OH2 is an oncolytic virus derived from herpes simplex type 2. A phase Ia/Ib clinical trial in China was conducted patients with unresected stage III–IV melanoma, the majority of whom had acral type, to assess safety and preliminary efficacy OH2. Methods The enrolled histologically confirmed unresectable III or advanced IV melanoma. In Ia, nine received single-dose treatment across three dose levels (10 6 , 10 7 8 CCID 50 /mL, where represents cell culture infectious 50%) while six...
Purpose: Ethnic differences are conspicuous in melanoma. This study is to obtain a comprehensive view of genomic landscape and better understanding the correlations gene mutation status with clinicopathologic characteristics disease prognosis Asian population.Experimental Design: A total 2,793 melanoma patient samples were retrospectively collected analyzed for mutations C-KIT, BRAF, NRAS, PDGFRA coding regions telomerase reverse transcriptase (TERT) promoter region by Sanger sequencing....
Mucosal melanoma (MM) is the second most common subtype in Asian populations. Deregulation of microRNAs (miRNAs) has been extensively investigated various cancers, including cutaneous melanoma. However, roles miRNAs MM are unclear. In this study, we carried out miRNA profiling MM, and clinical biological miR-23a-3p MM. Methods: expression was profiled by microarray analysis. The quantitated qRT-PCR a cohort 117 patients with its prognostic significance evaluated. effect demonstrated both...
Mucosal melanoma (MM) is a highly vascularized tumor with an extremely poor prognosis. In this randomized, open-label, phase II study, we characterized the efficacy and safety of bevacizumab in combination carboplatin plus paclitaxel (CPB) patients previously untreated advanced MM.Patients were randomly assigned 2:1 ratio to receive (area under curve, 5) (175 mg/m2) once every 4 weeks (CPB arm, 5 mg/kg) or without (CP arm) 2 weeks. Progression-free survival (PFS) was primary end point....
515 Background: RC48-ADC is a novel humanized anti-HER2 antibody-drug conjugate (ADC), which showed promising data in HER2-positive and even negative patients (pts) with metastatic urothelial carcinoma (mUC). Toripalimab an anti-PD-1 antibody durable antitumor effect for mUC. The combination may have synergistic effect. Initial RC48-C014 was previously presented (ASCO 2021); here we reported update on safety ORR. Methods: In dose-escalation cohort, pts received 1.5 or 2 mg/kg + 3mg/kg...
Background Melanoma in people of Asian descent presents primarily non-sun-exposed areas, such as acral and mucosal melanoma. Compared with the predominant sun-exposed area melanomas Caucasians, do not respond well to immunotherapy are associated a worse prognosis. Hence, there is an urgent need for improved treatment melanoma Asians. This phase Ib trial evaluated safety efficacy modified herpes simplex virus-1 oncolytic virus OrienX010 Chinese patients unresectable stage IIIC–IV Methods...
Acral melanoma, known for low tumor mutation burden, responds poorly to immunotherapy. A standard therapy is still lacking.
Abstract Background The clinicopathological and survival profiles across primary sites in acral melanoma (AM) are still controversial unclear. Methods This is a multi-center retrospective study. Clinicopathological data of AM patients diagnosed between 1 January 2000 31 December 2017 from 6 large tertiary hospitals China were extracted. Chi square tests used to compare basic characteristics sole, palm nail bed. Melanoma-specific (MSS) differences based on compared by log-rank multivariate...
4519 Background: RC48-ADC is a novel humanized anti-HER2 antibody-drug conjugate (ADC). A phase II clinical study showed that has good effect on locally advanced or metastatic urothelial carcinoma with HER2-positive expression failed standard chemotherapy. In the study, some patients HER2-postive immunohistochemistry (IHC 2+) but negative FISH test still benefited from treatment of RC48-ADC.This was to evaluate activity and safety in HER2-negative carcinoma. Methods: This an open-label,...
Can the Cytokine-induced killer (CIK) cells in combination with immune checkpoint inhibitor further improve efficacy of chemotherapy non-small cell lung cancer (NSCLC) patients? What are adverse reactions this therapy? But these problems not clear. Therefore, we conducted a phase 1b trial to evaluate safety and autologous CIK therapy combined Sintilimab, antibody against programmed death-1, plus untreated, advanced NSCLC patients.Patients stage IIIB/IIIC/IV received platinum-based doublet...
The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. alteration correlates with aggressive disease cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits patients advanced urothelial carcinoma .The information on pathologically proven detected status was collected from the database Peking University Cancer Hospital. expression, well its association characteristics and prognosis, analyzed.A total 284 consecutive were enrolled. positive...
4566 Background: Disitamab vedotin has shown promising data across a spectrum of HER2 expression in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who progressed on chemotherapy. This study was conducted to evaluate the safety and efficacy disitamab plus anti-PD-1 antibody carcinoma. Methods: is an open-label, multicenter, phase 1b/2 trial activity RC48-ADC combined toripalimab, humanized immunoglobin G 4 monoclonal against PD-1 mUC. Patients received at 1.5 2...
Our previous study found that runt‐related transcription factor‐2 (RUNX2) was upregulated in human epithelial ovarian cancer (EOC) tissues and may be involved tumor progression prognosis. The aim of this to investigate the mechanism by which RUNX2 is aberrantly expressed EOC. We firstly confirmed miRNA‐23b directly targets Then, ectopic expression miR‐23b significantly inhibited cell proliferation tumorigenicity regulating RUNX2. Furthermore, down‐regulation correlated with aggressiveness...